Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF12A, PDL 192(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12957MR)

This product GTTS-WQ12957MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets TNFRSF12A gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_016639.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 51330
UniProt ID Q9NP84
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF12A, PDL 192(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ12957MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ332MR IVTScrip™ mRNA-Anti-CD27, 1F5(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA 1F5
GTTS-WQ13347MR IVTScrip™ mRNA-Anti-PDCD1, PF-06801591(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PF-06801591
GTTS-WQ11709MR IVTScrip™ mRNA-Anti-IL13, MILR1444A(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MILR1444A
GTTS-WQ15046MR IVTScrip™ mRNA-Anti-CD47, SRF-231(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA SRF-231
GTTS-WQ11765MR IVTScrip™ mRNA-Anti-CTLA4, MK-1308(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MK-1308
GTTS-WQ11820MR IVTScrip™ mRNA-Anti-LAG3, MK-4280(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MK-4280
GTTS-WQ1386MR IVTScrip™ mRNA-Anti-IL1A&IL1B, ABT-981(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ABT-981
GTTS-WQ4598MR IVTScrip™ mRNA-Anti-KIR2DL1&KIR2DL2&KIR2DL3&KIR2DS1&KIR2DS2, BMS-986015(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-986015
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW